Press Release

CROs Continue to Choose Oracle to Support their Operations

AMS, EPS Corp., and Firma Clinical among newest contract research organizations to use Clinical One to meet market demands

Austin, TexasFebruary 12, 2024
CROs

Contract Research Organizations (CROs) continue to rely on Oracle to keep pace with competitive pressures, changing market requirements, and a lack of skilled talent. Since its inception in summer 2022, numerous CROs have joined the Oracle CRO growth initiative, including recent entrants AMS Advanced Medical Services GmbH, Firma Clinical, and EPS Corp., among many others. Through the initiative, CROs can evaluate, familiarize, train, and enable their users with Oracle Clinical One and demonstrate the power of the platform with their potential sponsors. This winning combination of Oracle’s life sciences expertise and platform technology help CROs win more business and run trials more efficiently.

“Our customers work with us based on our extensive experience and reliability competencies,” said Hassan Kazerooni, director, Data Management, AMS Advanced Medical Services GmbH. Working with Oracle through the CRO Growth Initiative has allowed us to expand our offering with Clinical One to offer the best technology options that match the needs of our customers for international clinical studies.”

As part of the CRO Growth Initiative, many CRO professionals have also taken advantage of the program’s accelerator that provides go-to-market benefits, technical enablers, and incentives that empower CROs to plan, execute, measure, and reward success in delivering expert services to their end customers with Clinical One.

“The opportunity to collaborate using Oracle’s Clinical One provides Firma Clinical the ability to be at the forefront of the ever-changing clinical trial technology environments,” said Lisa Squibb, associate vice president, Data Management, Firma Clinical. “With Oracle’s integrated platform, fair pricing, and overall expertise, we are able to bring our clients a high-quality data management experience that meets their needs and exceeds their expectations.”

“As the environment surrounding healthcare changes, the expectations placed on EPS as a pioneer of CROs in the Japan healthcare market have become even greater, and the roles required of us have broadened,” said Noriyuki Takai, board member, executive corporate officer, Global Research Business Headquarters, EPS Corporation. “EPS participates in Oracle’s CRO Growth Initiative, and the simple and user-friendly approach of Clinical One allows us to continue to take on efficient and proactive challenges as a reliable partner in the entire healthcare industry.”

Oracle’s CRO Growth Initiative benefits include:

  • Partnership management - Dedicated CRO-focused resources to help accelerate CRO services growth and success based on a mutually agreed business strategy.
  • Free training and enablement - Clinical One accreditation and flexible and robust training programs to help build sales and services expertise to win new business.
  • Business development support - Go-to-market strategies to help elevate CROs brand and RFx support for joint selling and bid defenses.
  • Growth incentives - Clinical One single trial service credits and a free non-production Clinical One cloud environment to allow users to evaluate, familiarize, and for 12 months.

“As the demand continues to grow and the expectation of faster, lower-cost trials accelerates, CROs are under greater pressure to deliver measurable results quickly,” said Seema Verma, executive vice president and general manager, Oracle Health and Oracle Life Sciences. “We created the CRO Growth Initiative to provide CROs the ability to use industry-leading technology to meet the needs of their clients with greater efficiency, speed, and accuracy.”

CROs work with Oracle because of its extensive experience and leading technologies in life sciences. Clinical One is a unified eClinical platform that harmonizes data, streamlines workflow, and saves significant time from study startup to study closeout. It enables stakeholders to have quick and easy access to the data needed to support critical decision-making, patient safety, and study oversight.

For more information about the Oracle CRO Growth Initiative visit: https://www.oracle.com/life-sciences/cro-growth-initiative/ and learn more about Clinical One at: https://www.oracle.com/life-sciences/clinical-research/clinical-one/

Contact Info

About Oracle Life Sciences

Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years’ experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements—empowering the Life Sciences industry to improve patient outcomes. Learn more at oracle.com/lifesciences

About Oracle

Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

Trademarks

Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.